Literature DB >> 19673624

Current concepts in colorectal cancer prevention.

Patricia A Thompson1, Eugene W Gerner.   

Abstract

Colorectal cancer chemoprevention, or chemoprophylaxis, is a drug-based approach to prevent colorectal cancer. Preventing colorectal adenomas with currently available agents demonstrates the promise of pharmacologic strategies directed at critical regulatory pathways. However, agent toxicity, lesion breakthrough and competing efficacy from endoscopy procedures challenge population-based implementation. This article reviews the role of colorectal cancer chemoprevention in the context of existing screening and surveillance guidelines and practice. Emphasis is placed on the role of the colorectal adenoma as a cancer precursor and its surrogacy in assessing individual risk and for evaluating chemoprevention efficacy. We discuss the importance of risk stratification for identifying subjects at moderate-to-high risk for colorectal cancer who are most likely to benefit from chemoprevention at an acceptable level of risk.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19673624      PMCID: PMC2921642          DOI: 10.1586/egh.09.28

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  141 in total

1.  Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence.

Authors:  David S Alberts; María Elena Martínez; Lisa M Hess; Janine G Einspahr; Sylvan B Green; A K Bhattacharyya; Jose Guillen; Mary Krutzsch; Ashok K Batta; Gerald Salen; Liane Fales; Kris Koonce; Dianne Parish; Mary Clouser; Denise Roe; Peter Lance
Journal:  J Natl Cancer Inst       Date:  2005-06-01       Impact factor: 13.506

2.  Combination chemoprevention of cancer.

Authors:  M B Sporn
Journal:  Nature       Date:  1980-09-11       Impact factor: 49.962

Review 3.  Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society.

Authors:  Sidney J Winawer; Ann G Zauber; Robert H Fletcher; Jonathon S Stillman; Michael J O'Brien; Bernard Levin; Robert A Smith; David A Lieberman; Randall W Burt; Theodore R Levin; John H Bond; Durado Brooks; Tim Byers; Neil Hyman; Lynne Kirk; Alan Thorson; Clifford Simmang; David Johnson; Douglas K Rex
Journal:  Gastroenterology       Date:  2006-05       Impact factor: 22.682

Review 4.  Surrogate end-point biomarkers as measures of colon cancer risk and their use in cancer chemoprevention trials.

Authors:  J G Einspahr; D S Alberts; S M Gapstur; R M Bostick; S S Emerson; E W Gerner
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1997-01       Impact factor: 4.254

Review 5.  Flat adenomas.

Authors:  Doug Speake; Deepak Biyani; Frank A Frizelle; Angus J M Watson
Journal:  ANZ J Surg       Date:  2007 Jan-Feb       Impact factor: 1.872

6.  Bile acid metabolism by fresh human colonic contents: a comparison of caecal versus faecal samples.

Authors:  L A Thomas; M J Veysey; G French; P B Hylemon; G M Murphy; R H Dowling
Journal:  Gut       Date:  2001-12       Impact factor: 23.059

Review 7.  Diet and cancer prevention: the roles of observation and experimentation.

Authors:  María Elena Martínez; James R Marshall; Edward Giovannucci
Journal:  Nat Rev Cancer       Date:  2008-09       Impact factor: 60.716

Review 8.  Aspirin and NSAIDs for the prevention of colorectal cancer.

Authors:  John A Baron
Journal:  Recent Results Cancer Res       Date:  2009

9.  Accuracy of CT colonography for detection of large adenomas and cancers.

Authors:  C Daniel Johnson; Mei-Hsiu Chen; Alicia Y Toledano; Jay P Heiken; Abraham Dachman; Mark D Kuo; Christine O Menias; Betina Siewert; Jugesh I Cheema; Richard G Obregon; Jeff L Fidler; Peter Zimmerman; Karen M Horton; Kevin Coakley; Revathy B Iyer; Amy K Hara; Robert A Halvorsen; Giovanna Casola; Judy Yee; Benjamin A Herman; Lawrence J Burgart; Paul J Limburg
Journal:  N Engl J Med       Date:  2008-09-18       Impact factor: 91.245

10.  Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas.

Authors:  Jason A Zell; Daniel Pelot; Wen-Pin Chen; Christine E McLaren; Eugene W Gerner; Frank L Meyskens
Journal:  Cancer Prev Res (Phila)       Date:  2009-03-03
View more
  6 in total

1.  Progress against cancer (1971-2011): how far have we come?

Authors:  A K Tiwari; H K Roy
Journal:  J Intern Med       Date:  2011-10-20       Impact factor: 8.989

2.  Intermittent Dosing with Sulindac Provides Effective Colorectal Cancer Chemoprevention in the Azoxymethane-Treated Mouse Model.

Authors:  Swati Chandra; Ariel C Nymeyer; Photini Faith Rice; Eugene W Gerner; Jennifer K Barton
Journal:  Cancer Prev Res (Phila)       Date:  2017-06-13

3.  Hesperidin alleviates oxidative stress and downregulates the expressions of proliferative and inflammatory markers in azoxymethane-induced experimental colon carcinogenesis in mice.

Authors:  Gowrikumar Saiprasad; Palanivel Chitra; Ramar Manikandan; Ganapasam Sudhandiran
Journal:  Inflamm Res       Date:  2013-02-02       Impact factor: 4.575

4.  Consensus on the Prevention, Screening, Early Diagnosis and Treatment of Colorectal Tumors in China: Chinese Society of Gastroenterology, October 14-15, 2011, Shanghai, China.

Authors:  Jing-Yuan Fang; Shu Zheng; Bo Jiang; Mao-De Lai; Dian-Chun Fang; Ying Han; Qian-Jiu Sheng; Jing-Nan Li; Ying-Xuan Chen; Qin-Yan Gao
Journal:  Gastrointest Tumors       Date:  2014-05-09

5.  DNA polymerase β as a novel target for chemotherapeutic intervention of colorectal cancer.

Authors:  Aruna S Jaiswal; Sanjeev Banerjee; Ritu Aneja; Fazlul H Sarkar; David A Ostrov; Satya Narayan
Journal:  PLoS One       Date:  2011-02-02       Impact factor: 3.240

6.  Differential influence of inositol hexaphosphate on the expression of genes encoding TGF-β isoforms and their receptors in intestinal epithelial cells stimulated with proinflammatory agents.

Authors:  Małgorzata Kapral; Joanna Wawszczyk; Stanisław Sośnicki; Ludmiła Węglarz
Journal:  Mediators Inflamm       Date:  2013-12-29       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.